Blood Cancers | Tumor

Cancer and Fatigue Go Together

May 15th 2024, 5:00pm

Article

As a cancer survivor, I’m pleading for more research on cancer related fatigue.

Certain Immunotherapy Drugs Not Recommended for Pregnant Women With Cancer

May 10th 2024, 9:23pm

Article

When possible, immune checkpoint inhibitors should be avoided in pregnant women with cancer due to lung inflammation and possible miscarriage, researchers found.

Social Support Is Key During BiTE Therapy for Blood Cancers

May 9th 2024, 7:30pm

Video

An oncology nurse discusses what patients should know before BiTE therapy, and what they can do if they do not have a social support system.

Nurse Says CAR-T Cell Therapy is a ‘Mind-Blowing’ Advancement

May 3rd 2024, 1:00pm

Video

For patients with blood cancers, CAR-T cell therapy has been a “mind-blowing” advancement for treatment in the cancer space.

Pelabresib Combo Leads to Outcomes Linked to Better Survival in Myelofibrosis

April 16th 2024, 7:00pm

Article

Pelabresib plus Jakafi led to a reduction in spleen size and was tolerable in patients with myelofibrosis, according to data from MANIFEST-2.

How COVID-19 Helped Me Cope Day to Day With Cancer

April 11th 2024, 5:00pm

Article

I was surprised that COVID-19 taught me how to cope with the daily annoyances of cancer.

Lower Childbirth Rates Shown in Women With MPNs

April 3rd 2024, 3:00pm

Article

Childbirth rates have been reduced by 22% in women with MPNs, compared with women without MPNs, researchers found.

FDA Approvals in the Blood Cancer Space from Early 2024

April 1st 2024, 7:00pm

Article

The Food and Drug Administration approved multiple new therapies for blood cancer over the last few months.

Elritercept Receives FDA Fast Track Designation for MDS Treatment

March 22nd 2024, 1:00pm

Article

The novel treatment elritercept received a Fast Track designation from the FDA to treat anemia in patients with MDS.

Blood Cancer Expert Talks CAR-T Cell Therapy Risks, Benefits

March 20th 2024, 7:00pm

Article

An FDA committee voted that the benefits of Carvykti outweigh the risks for myeloma treatment, though concerns about secondary malignancies remain.